TENAX THERAPEUTICS, INC. Available-for-sale Securities, Gross Unrealized Loss
TENAX THERAPEUTICS, INC. (TENX) reported Available-for-sale Securities, Gross Unrealized Loss of $435 for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2021-05-17
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2021-03-31 was $435.00, a 72.57% decline year-over-year.
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2020-12-31 was $108.00, a 40.26% increase year-over-year.
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2020-09-30 was $38.00, a 137.50% increase year-over-year.
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2020-06-30 was -$1.53K.
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for fiscal 2020 was $202.00, a 104.04% increase from fiscal 2019.
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for fiscal 2019 was $99.00, a 10.00% decline from fiscal 2018.
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for fiscal 2018 was $110.00.
- TENAX THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for fiscal 2015 was -$19.44K.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|---|---|---|
| 2021-03-31 | $435.00 10-Q · filed 2021-05-17 | $543.00 derived: sum of 2 quarters · filed 2021-05-17 | $581.00 derived: sum of 3 quarters · filed 2021-05-17 | -$949.00 derived: sum of 4 quarters · filed 2021-05-17 |
| 2020-12-31 | $108.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-16 | $146.00 derived: sum of 2 quarters · filed 2021-04-16 | -$1.38K derived: sum of 3 quarters · filed 2021-04-16 | $202.00 10-K/A · filed 2021-04-16 |
| 2020-09-30 | $38.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$1.49K derived: sum of 2 quarters · filed 2020-11-16 | $94.00 10-Q · filed 2020-11-16 | $171.00 derived: sum of 4 quarters · filed 2020-11-16 |
| 2020-06-30 | -$1.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $56.00 10-Q · filed 2020-08-14 | $133.00 derived: sum of 3 quarters · filed 2020-08-14 | $149.00 derived: sum of 4 quarters · filed 2020-08-14 |
| 2020-03-31 | $1.59K 10-Q · filed 2020-05-15 | $1.66K derived: sum of 2 quarters · filed 2020-05-15 | $1.68K derived: sum of 3 quarters · filed 2020-05-15 | $1.62K derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-12-31 | $77.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $93.00 derived: sum of 2 quarters · filed 2020-03-30 | $35.00 derived: sum of 3 quarters · filed 2020-03-30 | $99.00 10-K · filed 2020-03-30 |
| 2019-09-30 | $16.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$42.00 derived: sum of 2 quarters · filed 2019-11-14 | $22.00 10-Q · filed 2019-11-14 | |
| 2019-06-30 | -$58.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $6.00 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | $64.00 10-Q · filed 2019-05-15 | |||
| 2018-12-31 | $110.00 10-K · filed 2019-04-01 | |||
| 2015-07-31 | -$39.53K 10-Q · filed 2015-09-09 | -$25.68K derived: sum of 2 quarters · filed 2015-09-09 | $4.35K derived: sum of 3 quarters · filed 2015-09-09 | $7.50K derived: sum of 4 quarters · filed 2015-09-09 |
| 2015-04-30 | $13.85K derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-14 | $43.88K derived: sum of 2 quarters · filed 2015-07-14 | $47.03K derived: sum of 3 quarters · filed 2015-07-14 | -$19.44K 10-K · filed 2015-07-14 |
| 2015-01-31 | $30.03K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-03-17 | $33.18K derived: sum of 2 quarters · filed 2015-03-17 | -$33.29K 10-Q · filed 2015-03-17 | |
| 2014-10-31 | $3.15K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-12-15 | -$63.32K 10-Q · filed 2014-12-15 | ||
| 2014-07-31 | -$66.47K 10-Q · filed 2014-09-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |